View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
May 28, 2020updated 04 Aug 2022 1:43pm

Clinical trials disrupted due to Covid-19 slowly resume

By Miranda Mclaren

Many companies have announced that they are experiencing disruptions to their clinical trials for non-Covid-19 indications due to the strict lockdown measures that many countries have implemented. Many have delayed the initiation of planned trials or withdrawn the trials completely, and others have suspended enrolment in their ongoing trials or terminated the trials altogether.

The COVID-19 Dashboard on GlobalData’s Pharma Intelligence Center dynamically tracks both these disrupted trials and trials that have resumed activity. It reveals that more than 130 trials are currently resuming, and more trials are being added to this category daily.

To read more, please click here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena